HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hagen Kulbe Selected Research

Carcinoma (Carcinomatosis)

1/2022Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.
1/2022Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
4/2019APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
1/2019MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.
1/2018Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
1/2016Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hagen Kulbe Research Topics

Disease

28Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 11/2005
28Neoplasms (Cancer)
12/2021 - 01/2004
6Carcinoma (Carcinomatosis)
01/2022 - 01/2016
5Ovarian Epithelial Carcinoma
01/2022 - 11/2005
3Ascites
03/2016 - 07/2007
3Inflammation (Inflammations)
01/2012 - 07/2005
2Infections
11/2013 - 03/2011
2Necrosis
11/2013 - 07/2007
2Carcinogenesis
06/2011 - 02/2006
2Neoplasm Metastasis (Metastasis)
07/2007 - 01/2004
2Extranodal Extension
07/2007 - 01/2007
1Residual Neoplasm
01/2022
1Genomic Instability
12/2021
1Alcoholism (Alcohol Abuse)
10/2019
1Renal Cell Carcinoma (Grawitz Tumor)
03/2017
1Vaccinia
11/2013
1Papilloma (Papillomatosis)
06/2011
1Clear Cell Adenocarcinoma
04/2011
1Hypoxia (Hypoxemia)
04/2011
1Hypercalcemia (Milk Alkali Syndrome)
04/2011
1Breast Neoplasms (Breast Cancer)
07/2005
1Pathologic Processes
01/2004

Drug/Important Bio-Agent (IBA)

15CytokinesIBA
03/2016 - 01/2004
9Interleukin-6 (Interleukin 6)IBA
04/2015 - 02/2006
7Proteins (Proteins, Gene)FDA Link
01/2022 - 11/2005
7ChemokinesIBA
01/2014 - 01/2004
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2009 - 07/2005
5Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2018
5PlatinumIBA
12/2021 - 04/2011
5Messenger RNA (mRNA)IBA
04/2019 - 11/2005
5Chemokine ReceptorsIBA
03/2017 - 01/2004
3LigandsIBA
03/2017 - 01/2004
3AntibodiesIBA
01/2016 - 01/2012
3Infliximab (Remicade)FDA Link
03/2011 - 02/2006
3NF-kappa B (NF-kB)IBA
10/2009 - 07/2005
2LipidsIBA
04/2021 - 10/2018
2ParaffinIBA
01/2019 - 12/2018
2Aldehyde Dehydrogenase 1 FamilyIBA
01/2018 - 01/2017
2Small Interfering RNA (siRNA)IBA
03/2016 - 01/2012
2Neutralizing AntibodiesIBA
04/2015 - 01/2012
2Interleukin-17 (Interleukin 17)IBA
08/2014 - 10/2009
2Macrophage Migration-Inhibitory FactorsIBA
07/2007 - 01/2007
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2007 - 01/2007
2Metalloproteases (Metalloproteinases)IBA
04/2006 - 07/2005
1Transcription Factors (Transcription Factor)IBA
01/2022
1Biological ProductsIBA
01/2022
1Cell-Free Nucleic AcidsIBA
12/2021
1AntigensIBA
04/2021
1CopperIBA
10/2019
1Disulfiram (Antabuse)FDA Link
10/2019
1Pharmaceutical PreparationsIBA
10/2019
1EnzymesIBA
10/2019
1Cisplatin (Platino)FDA LinkGeneric
10/2019
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
04/2019
1Formaldehyde (Formol)FDA Link
01/2019
1AldehydesIBA
01/2018
1silmitasertibIBA
03/2016
1Protein Kinases (Protein Kinase)IBA
03/2016
1Casein Kinase II (Casein Kinase 2)IBA
03/2016
1Phosphotransferases (Kinase)IBA
03/2016
1B7-H1 AntigenIBA
01/2016
1Gefitinib (Iressa)FDA Link
04/2015
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
08/2014
1Lymphotoxin-alpha (Lymphotoxin)IBA
01/2014
1Lymphotoxin beta ReceptorIBA
01/2014
1Thymidine KinaseIBA
11/2013
1HMGB1 Protein (HMG1)IBA
11/2013
1Adenosine Triphosphate (ATP)IBA
11/2013
1Caspase 8 (Caspase-8)IBA
11/2013
1siltuximabIBA
09/2011
1anthraceneIBA
06/2011
1terephthalic acid (terephthalate)IBA
06/2011
1Angiogenesis InhibitorsIBA
04/2011
1Sunitinib (Sutent)FDA Link
04/2011
1InterleukinsIBA
04/2011
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
04/2011
1DNA (Deoxyribonucleic Acid)IBA
04/2011
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
10/2009
1Type I Tumor Necrosis Factor ReceptorsIBA
10/2009
1Interleukin-23 (Interleukin 23)IBA
10/2009
1Transforming Growth Factor beta1 (TGF beta 1)IBA
10/2009
1Peptides (Polypeptides)IBA
07/2009
1CTCE-9908IBA
07/2009
1Interleukin-10 (Interleukin 10)IBA
07/2007
1Chemotactic FactorsIBA
07/2007
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
01/2007
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2007
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
07/2005
1Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA
07/2005

Therapy/Procedure

6Therapeutics
12/2021 - 06/2008
1Investigational Therapies (Experimental Therapy)
01/2017
1Drug Therapy (Chemotherapy)
04/2011